Association of Childhood Growth Hormone Treatment With Long-term Cardiovascular Morbidity
Authors:
Open Access
- 1 February 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Pediatrics
- Vol. 175 (2) , e205199
Abstract
Treatment with recombinant human growth hormone (rhGH) has been in clinical use since 1985, with treatment indications now extending beyond growth hormone deficiency (GHD) to include an increasing number of conditions in which childhood short stature is not primarily due to deficient endogenous growth hormone secretion, such as small for gestational age (SGA) without catch-up growth or idiopathic short stature (ISS).1 Apart from regulating linear growth during childhood, growth hormone and its prime mediator, insulinlike growth factor 1, have several effects on the metabolism of fat, protein, and carbohydrates2 as well as on the cardiovascular system.3,4 Moreover, both excess levels of growth hormone and GHD have been associated with increased cardiovascular morbidity and mortality.5-7Keywords
This publication has 42 references indexed in Scilit:
- Pharmacological Interventions for Short Stature: Pros and Cons2013
- Growth Hormone and the Cardiovascular SystemCardiology in Review, 2012
- Metabolic Actions of Insulin-Like Growth Factor-I in Normal Physiology and DiabetesEndocrinology and Metabolism Clinics of North America, 2012
- Incidence of Diabetes Mellitus and Evolution of Glucose Parameters in Growth Hormone–Deficient Subjects During Growth Hormone Replacement TherapyDiabetes Care, 2011
- Current Indications for Growth Hormone Therapy for Children and Adolescents2010
- The Swedish personal identity number: possibilities and pitfalls in healthcare and medical researchEuropean Journal of Epidemiology, 2009
- Timing and Tempo of First-Year Rapid Growth in Relation to Cardiovascular and Metabolic Risk Profile in Early AdulthoodJAMA, 2009
- The GH–IGF‐I axis and the cardiovascular system: clinical implicationsClinical Endocrinology, 2008
- The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six monthsPharmacoepidemiology and Drug Safety, 2006
- Trajectories of Growth among Children Who Have Coronary Events as AdultsNew England Journal of Medicine, 2005